Nitrogenous compounds have significant biological activity and play a crucial role in the treatment of numerous diseases such as diabetes, Alzheimer’s, and cancer. Their ability to interact with various biological targets makes them valuable in drug development and therapeutic applications. Recent studies have highlighted their potential in developing more effective and targeted treatments.

The aim of this study is to synthesize and biologically evaluate new nitrogenous compound derivatives as potential anti-Alzheimer's and anti-cancer agents through advanced docking studies. This approach will involve assessing the compounds' interactions with specific biological targets implicated in Alzheimer's disease, such as Acetylcholinesterase, and cancer, such as Tubulin.

Furthermore, a comprehensive ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) analysis will be conducted to evaluate the pharmacokinetic profiles of these compounds. By combining these evaluations, the study aims to identify promising drug candidates with significant therapeutic potential and provide insights into their feasibility for future clinical development.

A new derivative of nitrogenous compounds has been successfully synthesized through a simple reaction, resulting in an excellent yield. These molecules underwent theoretical simulation studies to verify their anti-Alzheimer and anti-cancer effects, such as Acetylcholinesterase, and cancer, such as Tubulin.

This study demonstrates that these molecules possess significant bioactive properties, making them potential candidates for medicinal applications.